Advertisement

Galactonojirimycin derivatives restore mutant human β-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse

      Abstract

      Ten low molecular compounds analogous to galactose were screened for inhibition of human β-galactosidase activity. Among them, 1-deoxy-galactonojirimycin and N-(n-butyl)-deoxy-galactonojirimycin showed an inhibitory effect at high concentrations. However, they restored mutant enzyme activities expressed in enzyme-deficient knockout mouse fibroblasts and human β-galactosidosis fibroblasts at lower intracellular concentrations. This effect was more remarkable on GM1-gangliosidosis mutations (R201C, I51T, R201H, R457Q) than Morquio B disease mutations (W273L, Y83H). These low molecular compounds pass though the blood–brain barrier in mice. We hope that this new therapeutic approach will become clinically applicable in the near future.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fan J.-Q.
        • Ishii S.
        • Asano N.
        • Suzuki Y.
        Accelerated transport and mutation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
        Nat Med. 1999; 5: 112-115
        • Suzuki Y.
        • Oshima A.
        • Nanba E.
        β-Galactosidase deficiency (β-galactosidosis): GM1-gangliosidosis and Morquio B disease.
        in: Scriver C.R. Beaudet A.L. Sly W.S. Valle D. Childs B. Kinzler K.W. Vogelstein B. The metabolic and molecular bases of inherited disease. 8th ed. McGraw-Hill, New York2001: 3775-3809
        • Matsuda J.
        • Suzuki O.
        • Oshima A.
        • Ogura A.
        • Naiki M.
        • Suzuki Y.
        Neurological manifestations of knockout mice with β-galactosidase deficiency.
        Brain Dev. 1997; 19: 19-20
        • Matsuda J.
        • Suzuki O.
        • Oshima A.
        • Ogura A.
        • Noguchi Y.
        • Yamamoto Y.
        • et al.
        β-Galactosidase-deficient mouse as an animal model for GM1-gangliosidosis.
        Glycoconj J. 1997; 14: 729-736
        • Inagaki M.
        • Katsumoto T.
        • Nanba E.
        • Ohno K.
        • Suehiro S.
        • Takeshita K.
        Lysosomal glycosphingolipid storage in choloroquine-induced α-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease.
        Acta Neuropathol. 1993; 85: 272-279
        • Oshima A.
        • Yoshida K.
        • Itoh K.
        • Kase R.
        • Sakuraba H.
        • Suzuki Y.
        Intracellular processing and maturation of mutant gene products in hereditary β-galactosidase deficiency (β-galactosidosis).
        Hum Genet. 1994; 93: 109-114
        • Tohyama J.
        • Nanba E.
        • Ohno K.
        Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: identification of point mutations in Japanese patients with Lesch–Nyhan syndrome and hereditary gout and their permanent expression in an HPRT-deficient mouse cell line.
        Hum Genet. 1994; 93: 175-181
        • Sakuraba H.
        • Aoyagi T.
        • Suzuki Y.
        Galactosialidosis (β-galactosidase-neuraminidase deficiency): a possible role of serine-thiol protease in the degradation of β-galactosidase molecules.
        Clin Chim Acta. 1982; 125: 275-282
        • Jeyakumar M.
        • Butters T.D.
        • Cortina-Borja M.
        • Hunnam V.
        • Proia R.L.
        • Perry V.H.
        • et al.
        Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
        Proc Natl Acad Sci USA. 1996; 96: 6388-6393
        • Platt F.M.
        • Neises G.R.
        • Reinkensmeier G.
        • Townsend M.J.
        • Perry V.H.
        • Proia R.L.
        • et al.
        Prevention of lysosomal storage in Tay–Sachs mice treated with N-butyldeoxynojirimycin.
        Science. 1997; 276: 428-431